Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
A single arm, open label, prospective, phase II trial of Gefitinib retreatment for the
advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And
progressive disease should be observed with at least one prior regimen following previous
gefitinib failure.
Primary endpoint
- to assess Disease Control Rate (Remission + Stable disease)
Secondary endpoints
- to assess the progression free survival